Weaning Protocol for Cardene (Nicardipine) Infusion
Cardene (nicardipine) infusion should be gradually reduced to 3 mg/hr (30 mL/hr for 0.1 mg/mL concentration or 15 mL/hr for 0.2 mg/mL concentration) once blood pressure goals are achieved, then discontinued with transition to oral antihypertensive therapy initiated either simultaneously or 1 hour prior to stopping the infusion. 1
Discontinuation Protocol
The FDA-approved weaning strategy for Cardene IV follows this sequence:
After achieving target blood pressure with rapid titration: Decrease the infusion rate to 3 mg/hr (maintenance dose) 1
- For 0.1 mg/mL concentration: reduce to 30 mL/hr
- For 0.2 mg/mL concentration: reduce to 15 mL/hr
Timing of discontinuation: Once hemodynamic stability is maintained at the maintenance dose, the infusion can be stopped 1
Pharmacokinetic considerations: Discontinuation results in 50% offset of blood pressure effect within approximately 30 minutes 1
Transition to Oral Therapy
Two distinct pathways exist depending on the oral agent selected:
Transitioning to oral nicardipine: Administer the first oral dose 1 hour prior to discontinuing the IV infusion 1
Transitioning to a different oral antihypertensive: Initiate the oral agent upon discontinuation of Cardene IV 1
Critical Monitoring During Weaning
Continuous blood pressure and heart rate monitoring is mandatory throughout the weaning process 1. The ACC/AHA hypertension guidelines emphasize that IV antihypertensive infusions require continual hemodynamic surveillance 2.
If hypotension or tachycardia develops during weaning:
- Immediately discontinue further dose reduction
- Allow blood pressure to stabilize
- Restart infusion at lower doses (3-5 mg/hr) if needed
- Titrate upward gradually to maintain target blood pressure 1
Special Population Considerations
Slower weaning is required in patients with: 1
- Heart failure (risk of negative inotropic effects)
- Impaired hepatic function (reduced drug clearance)
- Renal impairment (prolonged drug effect)
In these populations, extend the observation period at each dose reduction step and consider smaller decremental changes.
Common Pitfalls to Avoid
Do not abruptly discontinue Cardene without transition therapy. The 30-minute offset means blood pressure can rise rapidly, potentially causing hypertensive rebound, particularly in patients with severe baseline hypertension.
Do not transition to oral therapy too early. Ensure hemodynamic stability is achieved and maintained at the 3 mg/hr maintenance dose before considering discontinuation.
Do not use the same timing for all oral agents. The 1-hour pre-discontinuation dosing applies specifically to oral nicardipine due to its pharmacokinetic profile; other agents should be started at the time of IV discontinuation.
Note: The question mentions "dopamine (Cardene)" which appears to be an error. Cardene is nicardipine (a calcium channel blocker), not dopamine (a catecholamine). The protocol above addresses Cardene/nicardipine weaning as this is the medication named in the primary question. Dopamine weaning follows entirely different protocols as it is a vasopressor/inotrope used in shock states, not a vasodilator for hypertension.